http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808272.html si-local-file:///var/storage/secattach/20260723/26808272.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808272.html Thu, 23 Jul 2026 16:15:00 -0400 O.02295732 STIM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808272.html si-local-file:///var/storage/secattach/20260723/26808272.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808272.html Thu, 23 Jul 2026 16:15:00 -0400 O.02295732 STIM http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808003.html si-local-file:///var/storage/secattach/20260723/26808003.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808003.html Thu, 23 Jul 2026 16:05:00 -0400 O.02295732 STIM http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808003.html si-local-file:///var/storage/secattach/20260723/26808003.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+23++Filed+by%3A+Naor+Nir/26808003.html Thu, 23 Jul 2026 16:05:00 -0400 O.02295732 STIM http://www.streetinsider.com/Analyst+Comments/Neuronetics+%28STIM%29+Reiterated+at+Market+Outperform+by+Citizens/26791181.html <p>Citizens analyst David Turkaly reiterated a Market Outperform rating and $7.00 price target on Neuronetics (NASDAQ: STIM).</p><p>The analyst commented, "We reiterate our Market Outperform rating and $7 price target on shares of Neuronetics. STIM's new CEO, Dan Reuvers, started with the company in late March, making 2Q26 his first full quarter at the helm. On its 1Q26 call, Mr. Reuvers outlined his high-level priorities including: 1) broadening NeuroStar's commercial reach by expanding go-to-market menu items, 2) optimizing clinic workflows and revenue cycle management, 3) the opportunity of its Compass Pathways (CMPS, NC) collaboration and psychedelic treatments broadly, and 4) prioritizing http://www.streetinsider.com/Analyst+Comments/Neuronetics+%28STIM%29+Reiterated+at+Market+Outperform+by+Citizens/26791181.html Tue, 21 Jul 2026 04:51:47 -0400 STIM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+09/26789803.html si-local-file:///var/storage/secattach/20260720/26789803.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+09/26789803.html Mon, 20 Jul 2026 16:10:00 -0400 O.02295732 STIM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+09/26789803.html si-local-file:///var/storage/secattach/20260720/26789803.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Neuronetics%2C+Inc.+++++++++For%3A+Jul+09/26789803.html Mon, 20 Jul 2026 16:10:00 -0400 O.02295732 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html <p>Neuronetics, Inc. (NASDAQ: STIM) announced several management changes, including the appointment of Nir Naor as Chief Financial Officer, effective July 23, 2026.</p> <p>Naor brings more than 20 years of finance and life sciences experience. He most recently served as CFO of Axogen (NASDAQ: AXGN), a peripheral nerve repair company, where he contributed to the company achieving profitability and cash flow positivity within one year. Previously, he held CFO roles at Arbor Pharmaceuticals, where he led its sale to Azurity Pharmaceuticals, and at the U.S./Americas business of Mölnlycke. Earlier in his career, he held senior finance roles at UCB and AstraZeneca, worked http://www.streetinsider.com/Management+Changes/Neuronetics+names+new+CFO%2C+promotes+executive%2C+and+loses+legal+chief/26789703.html Mon, 20 Jul 2026 16:05:20 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Press+Releases/Neuronetics+Appoints+Nir+Naor+Chief+Financial+Officer%3B+Announces+Additional+Management+Changes/26789693.html <ul type="disc"><li>Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experience</li><li>Cory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026</li><li>Andrew Macan to step down as Executive Vice President, Chief Legal Officer &amp; Corporate Secretary, effective August 15, 2026</li></ul> <p>MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that Nir Naor will be http://www.streetinsider.com/Press+Releases/Neuronetics+Appoints+Nir+Naor+Chief+Financial+Officer%3B+Announces+Additional+Management+Changes/26789693.html Mon, 20 Jul 2026 16:05:00 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM http://www.streetinsider.com/Press+Releases/Neuronetics+Appoints+Nir+Naor+Chief+Financial+Officer%3B+Announces+Additional+Management+Changes/26789693.html <ul type="disc"><li>Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experience</li><li>Cory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026</li><li>Andrew Macan to step down as Executive Vice President, Chief Legal Officer &amp; Corporate Secretary, effective August 15, 2026</li></ul> <p>MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that Nir Naor will be http://www.streetinsider.com/Press+Releases/Neuronetics+Appoints+Nir+Naor+Chief+Financial+Officer%3B+Announces+Additional+Management+Changes/26789693.html Mon, 20 Jul 2026 16:05:00 -0400 A.04758039 A.06822034 A.28503203 A.36189357 A.36549092 A.50215212 AXGN O.00092737 O.01848302 O.02295732 O.15658009 O.20026344 O.22202258 O.29459406 O.47642696 STIM